HealthDay: 'Neuroprotectant' drug could boost outcomes after stroke

UC's Broderick comments on study

A new study found using a "neuroprotectant" drug alongside the standard surgical removal of a blood clot may reduce the risk of death and disability following a stroke.

Researchers presenting data at the International Stroke Conference reported the medication, called ApTOLL, protects brain tissue from continuing damage by cooling down inflammation.

More than 150 people who had an ischemic stroke were enrolled in the study in France and Spain, either receiving ApTOLL at two different doses or a placebo medication in addition to mechanical blood clot removal.

The patients who received the higher dose of ApTOLL were four times less likely to die from stroke compared to the patients who received a placebo.

Joseph Broderick, MD, professor in UC’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician, commented on the study for HealthDay. He said the drug needs to be tested more thoroughly before becoming a standard of care.

"The data warrants further study in a phase 3 study, but differences seen in this trial may be due to small number of patients and imbalances in factors related to outcome," Broderick said, adding that a much larger trial would be needed to confirm the findings.

Read the HealthDay article.

Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati

 

Related Stories

2

A partnership to end pancreatic cancer

December 19, 2025

Since 2010, BSI Engineering has raised more than $1.2 million for pancreatic cancer research at the University of Cincinnati Cancer Center in honor of a friend and inspiration to BSI’s founders, Bryan Speicher.

3

Bazinga! UC physicist cracks ‘Big Bang Theory’ problem

December 19, 2025

A physicist at the University of Cincinnati and his colleagues figured out something two of America’s most famous fictional physicists couldn’t: theoretically how to produce subatomic particles called axions in fusion reactors.